Evaluating whether Fulgent Genetics (NASDAQ: FLGT) is a good purchase involves analyzing its transition away from legacy pandemic-era testing revenues toward a diversified, core clinical genetic testing and oncology screening business. Bullish market participants emphasize the company's exceptionally robust balance sheet with zero debt, management's aggressive share buyback programs, and deep valuation discounts relative to its tangible book value. Conversely, cautious analysts note bottom-line net losses and revised revenue guidance, making fundamental due diligence essential before investing.